Bridging the Gap
Since its inception in 2015, BioCanRx has built a highly performing translational engine for cancer immunotherapy. The network bridges the gap between promising early-stage technologies and their clinical evaluation by taking a comprehensive, multi-disciplinary, ecosystem approach.
Canada has a strong record of health discovery and invention but does not perform as well as it could at translating these discoveries to innovations and treatments. Along the translational path, there are several roadblocks thwarting cancer researchers.